<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00217971</url>
  </required_header>
  <id_info>
    <org_study_id>#4886-NIDA-09236-11</org_study_id>
    <secondary_id>P50DA009236</secondary_id>
    <secondary_id>P50DA009236-11</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00217971</nct_id>
  </id_info>
  <brief_title>Dronabinol Treatment for Marijuana Addiction</brief_title>
  <acronym>MARINOL</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of Dronabinol in the Treatment of Marijuana Addiction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if dronabinol decreases the symptoms of marijuana&#xD;
      addiction and withdrawal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Marijuana addiction is associated with significant withdrawal symptoms, including anxiety,&#xD;
      irritability, bodily discomfort, and insomnia. The purpose of this study is to determine the&#xD;
      effectiveness of dronabinol in reducing withdrawal symptoms.&#xD;
&#xD;
      During this twelve-week, double-blind, placebo-controlled study, study visits will occur&#xD;
      twice each week. During study visits, participants will receive either placebo or medication.&#xD;
      Throughout the study, all participants will receive individualized psychotherapy sessions. At&#xD;
      each study visit, vital signs, self-report ratings, and urine samples will be collected.&#xD;
      Participants will have a follow-up evaluation at month 6.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Abstinent From Marijuana During Weeks 7 and 8 of the Trial</measure>
    <time_frame>weeks 7 and 8</time_frame>
    <description>Timeline Followback self report data was collected. This daily report was used to assess the proportion of patients abstinent during weeks 7 and 8 of the clinical trial.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Marijuana Abuse</condition>
  <arm_group>
    <arm_group_label>Dronabinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dronabinol: 20mg bid for a daily maximum dose of 40mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronabinol</intervention_name>
    <description>Dronabinol</description>
    <arm_group_label>Dronabinol</arm_group_label>
    <other_name>Marinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  men and women between the ages of 18-60&#xD;
&#xD;
          -  Meets DSM-IV criteria for current marijuana dependence and reports marijuana as&#xD;
             primary drug of abuse&#xD;
&#xD;
          -  Individuals must report using marijuana at least 5 days a week and have a marijuana&#xD;
             positive urine drug screen on the day of study entry&#xD;
&#xD;
          -  Individuals must be capable of giving informed consent and capable of complying with&#xD;
             study procedures.&#xD;
&#xD;
          -  Women of child-bearing age will be included in the study provided that they are not&#xD;
             pregnant, based on the results of a blood pregnancy test drawn at the time of&#xD;
             screening. They must also agree to use a method of contraception with proven efficacy&#xD;
             and agree not to become pregnant during the study. To confirm this, blood pregnancy&#xD;
             tests will be repeated monthly. Women will be provided a full explanation of the&#xD;
             potential dangers of pregnancy while on the study medication. If a woman becomes&#xD;
             pregnant, the study medication will be discontinued.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Meets criteria for current psychiatric disorder requiring psychiatric intervention.&#xD;
             Disorders that are stable on psychotherapy or pharmacotherapy will not be&#xD;
             exclusionary. Individuals will be permitted to take prescribed zolpidem and zaleplon&#xD;
             if there is no evidence of dependence on these substances.&#xD;
&#xD;
          -  History of seizures&#xD;
&#xD;
          -  Known sensitivity to dronabinol&#xD;
&#xD;
          -  Unstable medical conditions&#xD;
&#xD;
          -  Physical dependence on any other drugs (excluding nicotine) that would require medical&#xD;
             detoxification&#xD;
&#xD;
          -  Currently taking psychotropic medication with benefit for any other illness than&#xD;
             treatment of insomnia&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Individuals who have exhibited suicidal or homicidal behavior within the past two&#xD;
             years or who have current active suicidal ideation.&#xD;
&#xD;
          -  Individuals with coronary vascular disease as indicated by history of abnormal ECG or&#xD;
             history of cardiac symptoms.&#xD;
&#xD;
          -  Unstable physical disorder which might make participation hazardous such as&#xD;
             uncontrolled hypertension (SBP &gt; 150, DBP&gt; 90, or HR &gt; 100 when sitting quietly),&#xD;
             acute hepatitis (patients with chronic mildly elevated transaminases &lt; 2-3X upper&#xD;
             limit of normal are acceptable), or medically unstable diabetes.&#xD;
&#xD;
          -  Subjects in professions in which even mild intoxication would be hazardous (e.g.,&#xD;
             police officer, bus driver, firefighter).&#xD;
&#xD;
          -  Individuals who are court-mandated to treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frances R Levin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Foundation for Mental Hygiene, Inc.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stars.columbia.edu</url>
    <description>Click here for the Substance Treatment and Abuse Research Service (STARS) website</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>September 13, 2011</results_first_submitted>
  <results_first_submitted_qc>October 19, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 1, 2011</results_first_posted>
  <last_update_submitted>April 22, 2019</last_update_submitted>
  <last_update_submitted_qc>April 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute on Drug Abuse (NIDA)</investigator_affiliation>
    <investigator_full_name>Frances R Levin</investigator_full_name>
    <investigator_title>Director of Substance Use Disorder</investigator_title>
  </responsible_party>
  <keyword>cannabis dependence</keyword>
  <keyword>dronabinol</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All participants were seeking outpatient treatment for problems related to marijuana use and were recruited by local advertising or by clinical referrals in the New York City metropolitan area. Recruitment ran from 3/05-8/09 and patients participated in the trial at a research clinic at Columbia University.</recruitment_details>
      <pre_assignment_details>The trial included a one-week placebo lead-in phase. Individuals who were able to significantly decrease their marijuana use during the first week of the study were not randomized. Participants who reported marijuana use less than twice a week during the placebo lead-in phase were considered placebo responders.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dronabinol</title>
          <description>Dronabinol: 20mg bid for a daily maximum dose of 40mg.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo:2 placebo capsules dosed bid for a total of 4 capsules per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non compliant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dronabinol</title>
          <description>Dronabinol: 20mg bid for a daily maximum dose of 40mg.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo:2 placebo capsules dosed bid for a total of 4 capsules per day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
            <count group_id="B2" value="77"/>
            <count group_id="B3" value="156"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.9" spread="10.8"/>
                    <measurement group_id="B2" value="38.4" spread="9.2"/>
                    <measurement group_id="B3" value="37.9" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Abstinent From Marijuana During Weeks 7 and 8 of the Trial</title>
        <description>Timeline Followback self report data was collected. This daily report was used to assess the proportion of patients abstinent during weeks 7 and 8 of the clinical trial.</description>
        <time_frame>weeks 7 and 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dronabinol</title>
            <description>Dronabinol: 20mg bid for a daily maximum dose of 40mg.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo:2 placebo capsules dosed bid for a total of 4 capsules per day</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Abstinent From Marijuana During Weeks 7 and 8 of the Trial</title>
          <description>Timeline Followback self report data was collected. This daily report was used to assess the proportion of patients abstinent during weeks 7 and 8 of the clinical trial.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed 2x/week for 12 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dronabinol</title>
          <description>Dronabinol: 20mg bid for a daily maximum dose of 40mg.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo:2 placebo capsules dosed bid for a total of 4 capsules per day</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>diabetes</sub_title>
                <description>One patient required hospitalization for worsening diabetes after study completion during the follow-up period.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>stomach flu</sub_title>
                <description>The fourth patient had a stomach virus and was hospitalized for dehydration and was released after several days.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>concussion</sub_title>
                <description>One patient was involved in an altercation with the police resulting in a hospitalization with eventual discharge.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthma</sub_title>
                <description>One patient had worsening of chronic asthma that was previously well-controlled, resulting in a brief hospitalization.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>GI upset</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Consequences of use are often long-term and more subtle. Thus, trying to initiate change over a relatively short period (i.e. patients in the present trial were maintained on the maximum dronabinol dose for only 6 weeks), may have been inadequate.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Frances R. Levin, M.D.</name_or_title>
      <organization>Columbia University</organization>
      <phone>(212) 543-5896</phone>
      <email>frl2@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

